Zydus Cadila launches fast tracked programme to develop vaccine for novel coronavirus

17 Feb 2020 Evaluate

Zydus Cadila has launched a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19) based on two approaches. The first approach deals with development of a DNA vaccine against the major viral membrane protein responsible for the cell entry of the novel coronavirus, now called COVID-19. The second approach deals with development of a live attenuated recombinant measles virus vectored vaccine against COVID-19.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×